KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

COLUMBUS-AD: phase III study of adjuvant encorafenib + binimetinib in resected stage IIB/IIC BRAF V600-mutated melanoma.

Alexander Cj van Akkooi, Axel Hauschild, Georgina V Long, Mario Mandala, Michal Kicinski, Anne-Sophie Govaerts, Isabelle Klauck, Monia Ouali, Paul C Lorigan, Alexander Mm Eggermont

Future Oncol 19(30) 2017-2027

PMID37665297
PMCID-
DOI10.2217/fon-2023-0414
发表日期2023-09-04
摘要

摘要

Stage IIB/IIC melanoma has a high risk of recurrence after surgical resection. While, for decades, surgery was the only option for high-risk stage II disease in most countries, adjuvant therapies now exist. Anti-programmed cell death protein 1 (PD-1) antibodies significantly improve recurrence-free survival versus placebo in patients with fully resected stage IIB/IIC melanoma. Combined BRAF MEK inhibitor therapy showed benefits in high-risk stage III and advanced disease; however, its role in patients with fully resected stage BRAF-mutated IIB/IIC melanoma is still unknown. Here we describe the rationale and design of the ongoing randomized, placebo-controlled COLUMBUS-AD trial, the first study of a BRAF-MEK inhibitor combination therapy (encorafenib + binimetinib) in patients with BRAF V600-mutated stage IIB/IIC melanoma.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。